

- Zollinger RM Jr. Primary neoplasms of the small intestine. *Am J Surg* 1986;151:654–658.
- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
- DiSario JA, Burt RW, Vargas H, et al. Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. *Am J Gastroenterol* 1994;89:699–701.
- Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. *Arch Surg* 2007;142:229–235.
- Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. *Cancer Causes Control* 2005;16:781–787.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71–96.
- Talamonti MS, Goetz LH, Rao S, et al. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. *Arch Surg* 2002;137:564–570.
- Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973–1990. *Int J Epidemiol* 1996;25:722–728.
- Neugut AI, Santos J. The association between cancers of the small and large bowel. *Cancer Epidemiol Biomarkers Prev* 1993;2:551–553.
- Scelo G, Boffetta P, Anderson A, et al. Associations between small intestine cancer and other primary cancers: an international population-based study. *Int J Cancer* 2006;118:189–196.
- Schiessling S, Kihm M, Ganschow P, et al. Desmoid tumour biology in patients with familial adenomatous polyposis coli. *Br J Surg* 2013;100:694–703.
- Ghoshal UC, Sengar V, Srivastava D. Colonic transit study technique and interpretation: can these be uniform globally in different populations with non-uniform colon transit time? *J Neurogastroenterol Motil* 2012;18:227–228.
- Kim SK. Small intestine transit time in the normal small bowel study. *Am J Roentgenol Radium Ther Nucl Med* 1968;104:522–524.
- Belchetz LA, Berk T, Bapat BV, et al. Changing causes of mortality in patients with familial adenomatous polyposis. *Dis Colon Rectum* 1996;39:384–387.
- Bjork J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. *Gastroenterology* 2001;121:1127–1135.
- Burke CA, Beck GJ, Church JM, et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. *Gastrointest Endosc* 1999;49:358–364.
- Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. *Int J Colorectal Dis* 2001;16:63–75.
- Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* 1993;71:677–685.
- Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. *Fam Cancer* 2005;4:211–218.
- Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics screening, differential diagnosis, and medicolegal ramifications. *Clin Genet* 2009;76:1–18.
- Morpurgo E, Vitale GC, Galandiuk S, et al. Clinical characteristics of familial adenomatous polyposis and management of duodenal adenomas. *J Gastrointest Surg* 2004;8:559–564.
- Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. *Dis Colon Rectum* 1993;36:1059–1062.
- Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. *Gastroenterology* 2005;128:590–599.
- Park JG, Kim DW, Hong CW, et al. Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. *Clin Cancer Res* 2006;12:3389–3393.
- Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. *Fam Cancer* 2001;1:57–60.
- Koomstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: is it time for surveillance? *Lancet Oncol* 2008;9:901–905.
- Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209–3215.
- Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. *Cell Mol Life Sci* 1999;55:735–750.
- Yamaguchi S, Ogata H, Katsumata D, et al. MUTYH-associated colorectal cancer and adenomatous polyposis. *Surg Today* 2014;44:593–600.
- Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→>T:A mutations in colorectal tumors. *Nat Genet* 2002;30:227–232.
- Maisonneuve P, Marshall BC, Knapp EA, et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. *J Natl Cancer Inst* 2013;105:122–129.
- Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. *Int J Clin Exp Pathol* 2012;5:852–862.
- von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. *Dis Colon Rectum* 2007;50:839–855.
- Sigel JE, Petras RE, Lashner BA, et al. Intestinal adenocarcinoma in Crohn's disease: a report of 30 cases with a focus on coexisting dysplasia. *Am J Surg Pathol* 1999;23:651–655.
- Lashner BA. Risk factors for small bowel cancer in Crohn's disease. *Dig Dis Sci* 1992;37:1179–1184.
- Pan SY, Morrison H. Epidemiology of cancer of the small intestine. *World J Gastrointest Oncol* 2011;3:33–42.
- Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. *Aliment Pharmacol Ther* 2006;23:1097–1104.
- Hemminki K, Li X, Sundquist J, et al. Cancer risks in ulcerative colitis patients. *Int J Cancer* 2008;123:1417–1421.
- Bernstein CN, Blanchard JF, Kliever E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer* 2001;91:854–862.
- Di Sabatino A, Biagi F, Gobbi PG, et al. How I treat enteropathy-associated T-cell lymphoma. *Blood* 2012;119:2458–2468.
- Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. *Gastroenterology* 2009;136:81–90.
- Silano M, Volta U, Mecchia AM, et al. Delayed diagnosis of coeliac disease increases cancer risk. *BMC Gastroenterology* 2007;7:8.
- Ripley D, Weinerman BH. Increased incidence of second malignancies associated with small bowel adenocarcinoma. *Can J Gastroenterol* 1997;11:65–68.
- Mohandas KM, Desai DC. Epidemiology of digestive tract cancers in India. V. Large and small bowel. *Indian J Gastroenterol* 1998;18:118–121.
- Chen CC, Neugut AI, Rotterdam H. Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. *Cancer Epidemiol Biomarkers Prev* 1994;3:205–207.
- Boffetta P, Hazelton WD, Chen Y, et al. Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine—a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. *Ann Oncol* 2012;23:1894–1898.
- Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. *Cancer Epidemiol Biomarkers Prev* 1998;7:243–251.
- Ciresi DL, Scholten DJ. The continuing clinical dilemma of primary tumors of the small intestine. *Am Surg* 1995;61:698–702.
- Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. *Am J Surg* 2010;199:797–803.
- Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. *Cancer* 2004;101:518–526.
- Talamonti MS, Goetz LH, Rao S, et al. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. *Arch Surg* 2002;137:564–570.
- Rodriguez-Bigas MA, Vasen HF, Lynch HT, et al. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC. *Cancer* 1998;83:240–244.
- Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447–1453.
- Negri E, Bosetti C, Vecchia C, et al. Risk factors for adenocarcinoma of the small intestine. *Int J Cancer* 1999;82:171–174.
- Green PH, Cellier C. Celiac disease. *N Engl J Med* 2007;357:1731–1743.
- Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. *Aliment Pharmacol Ther* 2004;19:287–293.
- Bessette JR, Maglinte DD, Kelvin FM, et al. Primary malignant tumors in the small bowel: a comparison of the small-bowel enema and conventional follow-through examination. *AJR Am J Roentgenol* 1989;153:741–744.
- Pilleul F, Penigaud M, Milot L, et al. Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. *Radiology* 2006;241:796–801.
- Van Weyenberg SJ, Meijerink MR, Jacobs MA, et al. MR enteroclysis in the diagnosis of small-bowel neoplasms. *Radiology* 2010;254:765–773.
- Minordi LM, Vecchioli A, Mirk P, et al. CT enterography with polyethylene glycol solution vs CT enteroclysis in small bowel disease. *Br J Radiol* 2011;84:112–119.
- Gore RM, Mehta UK, Newmark GM, et al. Diagnosis and staging of small bowel tumours. *Cancer Imaging* 2006;6:209–212.
- Balthazar EJ, Noordhoorn M, Megibow AJ, et al. CT of small-bowel lymphoma in immunocompetent patients and patients with AIDS: comparison of findings. *AJR Am J Roentgenol* 1997;168:675–680.
- Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. *Radiographics* 2003;23:283–304.

64. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. *Radiology* 2003;226:527–532.
65. Hong X, Choi H, Chusilp C, et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. *Radiographics* 2006;26:481–495.
66. Albert JG, Martiny F, Krummenerl A, et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. *Gut* 2005;54:1721–1727.
67. Masselli G, Gualdi G. MR Imaging of small bowel. *Radiology* 2012;264:333–348.
68. Albert JG, Martiny F, Krummenerl A, et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. *Gut* 2005;54:1721–1727.
69. Van Weyenberg SJ, Van Waesberghe JH, Ell C, et al. Enteroscopy and its relationship to radiological small bowel imaging. *Gastrointest Endosc Clin N Am* 2009;19:389–407.
70. Crusco F, Maselli PA, Pelliccia G, et al. Malignant small bowel neoplasms: spectrum of disease on MR imaging. *Radiol Med* 2010;115:1279–1291.
71. Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. *Q J Nucl Med Mol Imaging* 2008;52:441–454.
72. Cronin CG, Swords R, Truong MT, et al. Clinical utility of PET/CT in lymphoma. *AJR Am J Roentgenol* 2010;194:W91–W103.
73. Ullerich H, Franzius CH, Domagk D, et al. 18F-Fluorodeoxyglucose PET in a patient with primary small bowel lymphoma: the only sensitive method of imaging. *Am J Gastroenterol* 2001;96:2497–2499.
74. Cronin CG, Scott J, McDermott, et al. Utility of PET/CT in the evaluation of small bowel pathology. *Br J Radiol* 2012;85:1211–1221.
75. Mensink PB, Haringsma J, Kucharzik T, et al. Complications of double balloon enteroscopy: a multicenter survey. *Endoscopy* 2007;39:613–615.
76. Kita H, Yamamoto H, Yano T, et al. Double balloon endoscopy in two hundred fifty cases for the diagnosis and treatment of small intestinal disorders. *Inflammopharmacology* 2007;15:74–77.
77. Zhong J, Ma T, Zhang C, et al. A retrospective study of the application on double-balloon enteroscopy in 378 patients with suspected small-bowel diseases. *Endoscopy* 2007;39:208–215.
78. Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. *Gastrointest Endosc* 2001;53:216–220.
79. May A, Nachbar L, Wardak A, et al. Double-balloon enteroscopy: preliminary experience in patients with obscure gastrointestinal bleeding or chronic abdominal pain. *Endoscopy* 2003;35:985–991.
80. Cazzato IA, Cammarota G, Nista EC, et al. Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. *Dig Liver Dis* 2007;39:483–487.
81. May A, Nachbar L, Pohl J, et al. Endoscopic interventions in the small bowel using double balloon enteroscopy: feasibility and limitations. *Am J Gastroenterol* 2007;102:527–535.
82. Suzuki T, Matsushima M, Okita I, et al. Clinical utility of double-balloon enteroscopy for small intestinal bleeding. *Dig Dis Sci* 2007;52:1914–1918.
83. Imaoka H, Higaki N, Kumagi T, et al. Characteristics of small bowel tumors detected by double balloon endoscopy. *Dig Dis Sci* 2011;55:2366–2371.
84. Liao Z, Gao R, Xu C, et al. Indications and detection, completion, and retention rates of small-bowel endoscopy: a systematic review. *Gastrointest Endosc* 2009;71:280–286.
85. Bailey AA, Debinski HS, Appleyard MN, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. *Am J Gastroenterol* 2006;101:2237–2243.
86. Schwartz GD, Barkin JS. Small-bowel tumors detected by wireless capsule endoscopy. *Dig Dis Sci* 2007;52:1026–1030.
87. Bailey AA, Debinski HS, Appleyard MN, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. *Am J Gastroenterol* 2006;101:2237–2243.
88. Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate results of capsule endoscopy trials. *Endoscopy* 2005;37:960–965.
89. Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate to evaluate results of capsule endoscopy trials. *Endoscopy* 2005;37:960–965.
90. DeLeusse A, Vahedi K, Jian R, et al. Capsule endoscopy or push enteroscopy for first-line exploration of obscure gastrointestinal bleeding? *Gastroenterology* 2007;132:855–862.
91. Morgan D, Upchurch B, Chiorean M, et al. Spiral enteroscopy: prospective US multicenter study in patients with small bowel disorders. *Gastrointest Endosc* 2010;72:992–998.
92. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of yield of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. *Am J Gastroenterol* 2005;100:2407–2418.
93. Akerman PA, Agrawal D, Cantero D, et al. Spiral enteroscopy with the new DSB overtube: a novel technique for deep peroral small-bowel intubation. *Endoscopy* 2008;40:974–978.
94. Bilimoria KY, Bentrem DJ, Wayne DJ, et al. Small bowel cancer in United States: changes in epidemiology, treatment and survival over the last 20 years. *Ann Surg* 2009;249:63–71.
95. American Cancer Society. Small Intestine Cancer. <http://www.cancer.org/acs/groups/cid/documents/webcontent/003140.pdf.pdf>. Accessed December 13, 2013.
96. Zouhairi ME, Venner A, Charabaty A, et al. Small bowel adenocarcinoma. *Curr Treat Options Oncol* 2008;9:388–399.
97. Pan SY, Morrison H. Epidemiology of cancer of the small intestine. *World J Gastrointest Oncol* 2011;3:33–42.
98. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. *Nat Rev Clin Oncol* 2013;10:534–544.
99. Sellner F. Investigations on the significance of the adenoma carcinoma sequence in the small bowel. *Cancer* 1990;66:702–715.
100. Haan JC, Buffart TE, Eijk PP, et al. Small bowel adenocarcinoma copy number profiles are more closely related to colorectal cancer than to gastric cancers. *Ann Oncol* 2012;23:367–374.
101. Chan OT, Chen ZM, Chung F, et al. Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. *Am J Clin Pathol* 2010;134:880–885.
102. Overman MJ, Hu CY, Kopetz S, et al. A population-based comparison of adenocarcinoma of large and small intestine: insights into a rare disease. *Ann Surg Oncol* 2012;19:1439–1445.
103. Jess T, Winther KV, Binder V, et al. Intestinal and extraintestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen county, Denmark. *Ailment Pharmacol Ther* 2004;19:287–293.
104. Jess T, Gørgø M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of a population based cohort. *Am J Gastroenterol* 2005;100:2724–2729.
105. Green PH, Fleischer AT, Bhagat G, et al. Risk of malignancy in patients with Celiac disease. *Am J Med* 2003;115:191–195.
106. Lee HJ, Lee OJ, Jang KT, et al. Combined loss of E-cadherin and aberrant  $\beta$ -catenin protein expression correlates with poor prognosis for small intestinal adenocarcinomas. *Am J Clin Pathol* 2013;139:167–176.
107. Murata M, Iwao K, Miyoshi Y, et al. Molecular and biological analysis of carcinoma of small intestine: beta-catenin gene mutation by interstitial deletion involving exon 3 and replication error phenotype. *Am J Gastroenterol* 2000;95:1576–1580.
108. Breuhahan K, Singh S, Blaker H. Large scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis. *J Pathol* 2008;215:300–307.
109. Ilyas M, Tomlinson IP, Bodmer WF. Beta-catenin mutations in the cell lines established from human colorectal cancers. *Proc Natl Acad Sci U S A* 1997;94:10330–10334.
110. Bläker H, von Herbay A, Penzel R, et al. Genetics of adenocarcinoma of small intestine: frequent deletions at chromosome 18q and mutations of SMAD4 gene. *Oncogene* 2002;21:158–164.
111. Bläker H, Aulmann S, Helmchen B, et al. Loss of SMAD4 function in small intestinal adenocarcinoma: comparison of genetic and immunohistochemical findings. *Pathol Res Pract* 2004;200:1–7.
112. Rashid A, Hamilton SR. Genetic alterations in sporadic and Crohn's associated adenocarcinomas of small intestine. *Gastroenterology* 1997;113:127–135.
113. Nishiyama K, Yao T, Yonemasu H, et al. Overexpression of p53 protein and point mutation of K-ras genes in primary carcinoma of small intestine. *Oncol Rep* 2002;9:293–300.
114. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–5257.
115. Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterization of adenocarcinoma of small intestine. *Br J Cancer* 2010;102:144–150.
116. Plank M, Ericson K, Piotrowska Z, et al. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of small intestine. *Cancer* 2003;97:1551–1557.
117. Diosdado B, Buffart TW, Watkins R, et al. High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. *Clin Cancer Res* 2010;16:1391–1401.
118. Fu T, Pappou EP, Guzzetta AA, et al. CpG island methylator phenotype-positive tumours in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. *Clin Cancer Res* 2012;18:4743–4752.
119. Potter DD, Murray JA, Donohue JH, et al. The role of defective mismatch repair in small bowel adenocarcinoma in celiac disease. *Cancer Res* 2004;64:7073–7077.
120. Howe JR, Kamell LH, Menck HR, et al. American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of national cancer database 1985–1995. *Cancer* 1999;86:2693–2706.
121. Overman MJ, Hu CY, Wolff RA, et al. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. *Cancer* 2010;116:5374–5382.
122. Barnes G Jr, Romero L, Hess KR, et al. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. *Ann Surg Oncol* 1994;1:73–78.

123. Bakaeen FG, Murr MM, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma? *Arch Surg* 2000;135:635–641.
124. Kaklamanos IG, Bathe OF, Franceschi D, et al. Extent of resection in the management of duodenal adenocarcinoma. *Am J Surg* 2000;179:37–41.
125. Joesting DR, Beart RW Jr, van Heerden JA, et al. Improving survival in adenocarcinoma of the duodenum. *Am J Surg* 1981;141:228–231.
126. Poultsides GA, Huang LC, Camerson JL, et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. *Ann Surg Oncol* 2012;19:1928–1935.
127. Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. *Am J Gastroenterol* 2006;101:2826–2832.
128. Sohn TA, Lillemoie KD, Cameron JL, et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. *J Gastrointest Surg* 1998;2:79–87.
129. Overman MJ, Kopetz S, Lin E, et al. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. *Acta Oncol* 2010;49:474–479.
130. Kelsey CR, Nelson JW, Willett CG, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2007;69:1436–1441.
131. Fishman PN, Pond GR, Moore MJ, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. *Am J Clin Oncol* 2006;29:225–231.
132. Koo DH, Yun SC, Hong YS, et al. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. *BMC Cancer* 2011;11:205.
133. Czykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. *Clin Oncol (R Coll Radiol)* 2007;19:143–149.
134. Ouriel K, Adams JT. Adenocarcinoma of the small intestine. *Am J Surg* 1984;147:66–71.
135. Locher C, Malka D, Boige V, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. *Oncology* 2005;69:290–294.
136. Zaanan A, Gauthier M, Malka D, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicentre AGEO study. *Cancer* 2011;117:1422–1428.
137. Jeurnink SM, van Eijck CH, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol* 2007;7:18.
138. Ercolani G, Grazi GL, Ravaoli M, et al. The role of liver resections for non-colorectal, nonneuroendocrine metastases: experience with 142 observed cases. *Ann Surg Oncol* 2005;12:459–466.
139. Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal non-endocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. *Ann Surg* 2006;244:524–535.
140. Yankai S, Stewart J, Levine E. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. *Am Surg* 2013;79:644–648.
141. Bessette JR, Maglente DD, Kelvin FM, et al. Primary malignant tumors in the small bowel: a comparison of the small-bowel enema and conventional follow-through examination. *AJR Am J Roentgenol* 1989;153:741–744.
142. Courtsoyiannis N, Makó E. Imaging of primary small intestinal tumours by enteroclysis and CT with pathological correlation. *Eur Radiol* 1997;7:625–642.
143. Buckley JA, Fishman EK. CT evaluation of small bowel neoplasms: spectrum of disease. *Radiographics* 1998;18:379–392.
144. Buckley JA, Siegelman SS, Jones B, et al. The accuracy of CT staging of small bowel adenocarcinoma: CT/pathologic correlation. *J Comput Assist Tomogr* 1997;21:986–991.
145. Buckley JA, Jones B, Fishman EK. Small bowel cancer. Imaging features and staging. *Radiol Clin North Am* 1997;35:381–402.
146. Laurent F, Drouillard J, Lecesne R, et al. CT of small-bowel neoplasms. *Semin Ultrasound CT MR* 1995;16:102–111.
147. Maglente DT, Reyes BL. Small bowel cancer. Radiologic diagnosis. *Radiol Clin North Am* 1997;35:361–380.
148. Horton KM, Juluru K, Montgomery E, et al. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. *J Comput Assist Tomogr* 2004;28:811–817.
149. Horton KM, Fishman EK. The current status of multidetector row CT and three-dimensional imaging of the small bowel. *Radiol Clin North Am* 2003;41:199–212.
150. Dudiak KM, Johnson CD, Stephens DH. Primary tumors of the small intestine: CT evaluation. *AJR Am J Roentgenol* 1989;152:995–998.
151. Horton KM, Fishman EK. Multidetector-row computed tomography and 3-dimensional computed tomography imaging of small bowel neoplasms: current concept in diagnosis. *J Comput Assist Tomogr* 2004;28:106–116.
152. Ramachandran I, Sinha R, Rajesh A, et al. Multidetector row CT of small bowel tumours. *Clin Radiol* 2007;62(7):607.
153. Maglente DD, Sandrasegaran K, Lapps JC. CT enteroclysis: techniques and applications. *Radiol Clin North Am* 2007;45:289–301.
154. Pilleul F, Penigaud M, Milot L, et al. Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. *Radiology* 2006;241:796–801.
155. Bender GN, Timmons JH, Williard WC, et al. Computed tomographic enteroclysis: one methodology. *Invest Radiol* 1996;31:43–49.
156. Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. *Gastrointest Endosc* 2001;53:216–220.
157. May A, Nachbar L, Wardak A, et al. Double-balloon enteroscopy: preliminary experience in patients with obscure gastrointestinal bleeding or chronic abdominal pain. *Endoscopy* 2003;35:985–991.
158. Mensink PB, Haringsma J, Kucharzik T, et al. Complications of double balloon enteroscopy: a multicenter survey. *Endoscopy* 2007;39:613–615.
159. Kita H, Yamamoto H, Yano T, et al. Double balloon endoscopy in two hundred fifty cases for the diagnosis and treatment of small intestinal disorders. *Inflammopharmacology* 2007;15:74–77.
160. Suzuki T, Matsushima M, Okita I, et al. Clinical utility of double-balloon enteroscopy for small intestinal bleeding. *Dig Dis Sci* 2007;52:1914–1918.
161. Zhong J, Ma T, Zhang C, et al. A retrospective study of the application on double-balloon enteroscopy in 378 patients with suspected small-bowel diseases. *Endoscopy* 2007;39:208–215.
162. Cazzato IA, Cammarota G, Nista EC, et al. Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. *Dig Liver Dis* 2007;39:483–487.
163. May A, Nachbar L, Pohl J, et al. Endoscopic interventions in the small bowel using double balloon enteroscopy: feasibility and limitations. *Am J Gastroenterol* 2007;102:527–535.
164. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. *Am J Gastroenterol* 2005;100:2407–2418.
165. Liao Z, Gao R, Xu C, et al. Indications and detection, completion, and retention rates of small-bowel endoscopy: a systematic review. *Gastrointest Endosc* 2009;71:280–286.
166. Schwartz GD, Barkin JS. Small-bowel tumors detected by wireless capsule endoscopy. *Dig Dis Sci* 2007;52:1026–1030.
167. Mazzarolo S, Brady P. Small bowel capsule endoscopy: a systematic review. *South Med J* 2007;100:274–280.
168. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003;97:934–959.
169. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. *Ann Surg* 2004;240:117–122.
170. Stinner B, Kisker O, Zielke A, et al. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. *World J Surg* 1996;20:183–188.
171. Akerström G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. *Acta Oncol* 1991;30:547–553.
172. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. *World J Surg* 1990;14:377–383.
173. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. *Ann Surg* 1999;229:815–821.
174. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. *Cancer* 2005;103:1587–1595.
175. Soga J. Carcinoids of the small intestine: a statistical evaluation of 1102 cases collected from the literature. *J Exp Clin Cancer Res* 1997;16:353–363.
176. Akerström G, Hellman P. Surgery on neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab* 2007;21:87–109.
177. Hellman P, Lundström T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. *World J Surg* 2002;26:991–997.
178. Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. *Surgery* 2006;140:891–897.
179. Søreide JA, van Heerden JA, Thompson GB, et al. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. *World J Surg* 2000;24:1431–1436.
180. Gronbech JE, Søreide O, Bergan A. The role of resective surgery in the treatment of the carcinoid syndrome. *Scand J Gastroenterol* 1992;27:433–437.
181. McEntee GP, Nagorney DM, Kvols LK. Cytoreductive hepatic surgery for neuroendocrine tumors. *Surgery* 1990;108:1091–1096.
182. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. *J Am Coll Surg* 2003;197:29–37.
183. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. *Surg Oncol Clin North Am* 2003;12:231–242.
184. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. *Ann Surg Oncol* 2006;13:572–581.
185. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. *Cancer J* 2003;9:261–267.
186. Kulke M. Advances in the treatment of neuroendocrine tumors. *Curr Treat Options Oncol* 2005;6:397–409.

187. Tiensuu Janson EM, Ahlström H, Andersson T, et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. *Eur J Cancer* 1992;28:1647–1650.
188. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. *Cancer* 1991;67:33–36.
189. Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. *Ann Oncol* 2001;12:S41–S45.
190. Kwekkeboom DJ, Teunissen JJ, Kam BL, et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. *Hematol Oncol Clin North Am* 2007;21:561–573.
191. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. *Hematol Oncol Clin North Am* 2007;21:575–581.
192. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. *N Engl J Med* 1986;315:663–666.
193. Kvols LK, Moertel CG, Schutt AJ, et al. Treatment of the malignant carcinoid syndrome with a long acting somatostatin analogue (SMS 201–995): preliminary evidence that more is not better. *Proc Am Soc Clin Oncol* 1987;6:95.
194. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. *Blood* 2006;107:3034–3044.
195. Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. *Gastroenterology* 2000;119:1191–1202.
196. Koniaris LG, Drugas G, Katzman PJ, et al. Management of gastrointestinal lymphoma. *J Am Coll Surg* 2003;197:127–141.
197. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. *Blood* 2004;104:3009–3020.
198. Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. *Gut* 2007;56:1373–1378.
199. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. *Arch Pathol Lab Med* 2006;130:1466–1478.
200. Blanke C, Eisenberg BL, Heinrich M. Epidemiology of GIST. *Am J Gastroenterol* 2005;100:2366.
201. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. *J Am Coll Surg* 2006;202:623–629.
202. Nilsson B, Bummig P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the pre-imatinib mesylate era—a population-based study in western Sweden. *Cancer* 2005;103:821–829.
203. Tryggvason G, Kristmundsson T, Orvar K, et al. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990–2003. *Dig Dis Sci* 2007;52:2249–2253.
204. Tryggvason G, Gislason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. *Int J Cancer* 2005;117:289–293.
205. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin Diagn Pathol* 2006;23:70–83.
206. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). *Mod Pathol* 2000;13:1134–1142.
207. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Hum Pathol* 2002;33:459–465.
208. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Int J Surg Pathol* 2002;10:81–89.
209. Pitsinis V, Khan AZ, Cranshaw I, et al. Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. *Hepatogastroenterology* 2007;54:606–608.
210. Feliu X, Besora P, Claveria R, et al. Laparoscopic treatment of gastric tumors. *J Laparoendosc Adv Surg Tech A* 2007;17:147–152.
211. Novitsky YW, Kercher KW, Sing RF, et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. *Ann Surg* 2006;243:738–745.
212. Nguyen SQ, Divino CM, Wang JL, et al. Laparoscopic management of gastrointestinal stromal tumors. *Surg Endosc* 2006;20:713–716.
213. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009;373:1097–1104.
214. DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) Intergroup phase 2 trial. *Ann Surg* 2013;258:422–429.
215. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26:620–625.
216. Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). *J Clin Oncol* 2009;27:abst 10550.
217. Cassier PA, Blesius AA, Perol D, et al. Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial. *J Clin Oncol* 2009;27:abst 10551.
218. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–523.
219. Raymond E, Dahan L, Raouf JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:501–513.
220. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:295–302.
221. Bender GN, Maglinte DD, McLarny JH, et al. Malignant melanoma: patterns of metastasis to the small bowel, reliability of imaging studies, and clinical relevance. *Am J Gastroenterol* 2001;96:2392–2400.
222. Berger A, Cellier C, Daniel C, et al. Small bowel metastases from primary carcinoma of the lung: clinical findings and outcome. *Am J Gastroenterol* 1999;94:1884–1887.
223. Buckley JA, Fishman EK. CT evaluation of small bowel neoplasms: spectrum of disease. *Radiographics* 1998;18:379–392.
224. Eskelinen M, Pasanen P, Kosma VM, Alhava E. Primary malignant schwannoma of the small bowel. *Ann Chir Gynaecol* 1991;81:326–328.
225. Levy AD, Quiles AM, Miettinen M, et al. Gastrointestinal schwannomas: CT features with clinicopathologic correlation. *Am J Roentgenol* 2005;184:797–802.
226. Kovach SJ, Fischer AC, Katzman PJ, et al. Inflammatory myofibroblastic tumors. *J Surg Oncol* 2006;94:385–391.
227. Day DL, Sane S, Dehner LP. Inflammatory pseudotumor of the mesentery and small intestine. *Pediatr Radiol* 1986;16:210–215.
228. Arts R, Bosscha K, Ranschaert E, et al. Small bowel leiomyosarcoma: a case report and literature review. *Turk J Gastroenterol* 2012;23:381–384.
229. Deek KB, Silberman H. Leiomyosarcomas of the small intestine. *Cancer* 1979;44:323–325.
230. Akwari OE, Dozois RR, Weiland LH, et al. Leiomyosarcoma of the small and large bowel. *Cancer* 1978;42:1375–1384.
231. Ashley SW, Wells SA Jr. Tumors of the small intestine. *Semin Oncol* 1988;15:116–128.
232. Shimer GR, Helwig EB. Inflammatory fibroid polyps of the intestine. *Am J Clin Pathol* 1984;81:708–714.
233. Harned RK, Buck JL, Shekitka KM. Inflammatory fibroid polyps of the gastrointestinal tract: radiologic evaluation. *Radiology* 1992;182:863–866.
234. Jones IT, Jagelman DG, Fazio VW, et al. Desmoid tumors in familial polyposis coli. *Ann Surg* 1986;204:94–97.
235. Dickson PV, Pollock R. Surgical management of desmoid tumors. In: Litchman C, ed. *Desmoid Tumors*. Netherlands: Springer, 2012:77–90.
236. Alman B. Desmoid tumors: are they benign or malignant? In: Litchman C, ed. *Desmoid Tumors*. Netherlands: Springer, 2012:195–203.
237. de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). *Cancer* 2010;116:2258–2265.
238. Reitamo JJ, Schelmin TM, Häyry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. *Am J Surg* 1986;151:230–237.
239. Sachs DL, Lowe L, Chang AE, et al. Do primary small intestinal melanomas exist? Report of a case. *J Am Acad Dermatol* 1999;41:1042–1044.